Literature DB >> 27105574

TGF-β induces SOX2 expression in a time-dependent manner in human melanoma cells.

Kasia Weina1,2, Huizi Wu1,2,3, Nathalie Knappe1,2, Elias Orouji1,2, Daniel Novak1,2, Mathias Bernhardt1,2, Laura Hüser1,2, Lionel Larribère1,2, Viktor Umansky1,2, Christoffer Gebhardt1,2, Jochen Utikal1,2.   

Abstract

The sry-related high-mobility box (SOX)-2 protein has recently been proven to play a significant role in progression, metastasis, and clinical prognosis spanning several cancer types. Research on the role of SOX2 in melanoma is limited and currently little is known about the mechanistic function of this gene in this context. Here, we observed high expression of SOX2 in both human melanoma cell lines and primary melanomas in contrast to melanocytic nevi. This overexpression in melanoma can, in part, be explained by extra gene copy numbers of SOX2 in primary samples. Interestingly, we were able to induce SOX2 expression, mediated by SOX4, via TGF-β1 stimulation in a time-dependent manner. Moreover, the knockdown of SOX2 impaired TGF-β-induced invasiveness. This phenotype switch can be explained by SOX2-mediated cross talk between TGF-β and non-canonical Wnt signaling. Thus, we propose that SOX2 is involved in the critical TGF-β signaling pathway, which has been shown to correlate with melanoma aggressiveness and metastasis. In conclusion, we have identified a novel downstream factor of TGF-β signaling in melanoma, which may have further implications in the clinic.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  SOX2; TGF-β signaling; melanoma

Mesh:

Substances:

Year:  2016        PMID: 27105574     DOI: 10.1111/pcmr.12483

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  17 in total

1.  New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging.

Authors:  Hailey E Brighton; Steven P Angus; Tao Bo; Jose Roques; Alicia C Tagliatela; David B Darr; Kubra Karagoz; Noah Sciaky; Michael L Gatza; Norman E Sharpless; Gary L Johnson; James E Bear
Journal:  Cancer Res       Date:  2017-11-27       Impact factor: 12.701

Review 2.  SOX4: The unappreciated oncogene.

Authors:  Carlos S Moreno
Journal:  Semin Cancer Biol       Date:  2019-08-21       Impact factor: 15.707

3.  Sox2 is dispensable for primary melanoma and metastasis formation.

Authors:  S M Schaefer; C Segalada; P F Cheng; M Bonalli; V Parfejevs; M P Levesque; R Dummer; S K Nicolis; L Sommer
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867

4.  Single-cell transcriptomics identifies master regulators of neurodegeneration in SOD1 ALS iPSC-derived motor neurons.

Authors:  Seema C Namboori; Patricia Thomas; Ryan Ames; Sophie Hawkins; Lawrence O Garrett; Craig R G Willis; Alessandro Rosa; Lawrence W Stanton; Akshay Bhinge
Journal:  Stem Cell Reports       Date:  2021-11-11       Impact factor: 7.765

5.  Acetylsalicylic acid inhibits the growth of melanoma tumors via SOX2-dependent-PAF-R-independent signaling pathway.

Authors:  Anita Thyagarajan; Jeremiah Saylae; Ravi P Sahu
Journal:  Oncotarget       Date:  2017-07-25

6.  Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response.

Authors:  Mathias Bernhardt; Daniel Novak; Yassen Assenov; Elias Orouji; Nathalie Knappe; Kasia Weina; Maike Reith; Lionel Larribere; Christoffer Gebhardt; Christoph Plass; Viktor Umansky; Jochen Utikal
Journal:  Stem Cell Reports       Date:  2017-04-06       Impact factor: 7.765

7.  MiR-34c downregulation leads to SOX4 overexpression and cisplatin resistance in nasopharyngeal carcinoma.

Authors:  Pierre-Antoine Bissey; Mona Teng; Jacqueline H Law; Wei Shi; Jeff P Bruce; Valentin Petit; Sai W Tsao; Kenneth W Yip; Fei-Fei Liu
Journal:  BMC Cancer       Date:  2020-06-26       Impact factor: 4.430

Review 8.  Functional characterization of SOX2 as an anticancer target.

Authors:  Shizhen Zhang; Xiufang Xiong; Yi Sun
Journal:  Signal Transduct Target Ther       Date:  2020-07-29

9.  LncRNA SOX2OT promotes temozolomide resistance by elevating SOX2 expression via ALKBH5-mediated epigenetic regulation in glioblastoma.

Authors:  Boyang Liu; Jian Zhou; Chenyang Wang; Yajie Chi; Quantang Wei; Zhao Fu; Changlin Lian; Qiongzhen Huang; Chenxin Liao; Zhao Yang; Huijun Zeng; Ningbo Xu; Hongbo Guo
Journal:  Cell Death Dis       Date:  2020-05-21       Impact factor: 8.469

10.  Sox2 is required for tumor development and cancer cell proliferation in osteosarcoma.

Authors:  Giulia Maurizi; Narendra Verma; Abhilash Gadi; Alka Mansukhani; Claudio Basilico
Journal:  Oncogene       Date:  2018-05-10       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.